A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease
Public ClinicalTrials.gov record NCT01074125. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 4-Week Dose-Ranging and Efficacy Trial of KRX-0502 (Ferric Citrate) in Patients With End-Stage Renal Disease (ESRD) Following a Two-Week Washout Period
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a research study for people with high blood phosphorus levels who are on dialysis. This medical condition can cause weakening of the bones and damage other organs. This can lead to many health problems, and sometimes death. Phosphorus is in much of the food we eat, and is helpful to us in small amounts. Patients with kidney failure have trouble getting rid of the phosphorus eaten in food. Dialysis can help remove some of the phosphorus, but often patients must take a phosphate binder like PhosLo®, Renagel®, or Renvela® to bring the blood phosphorus levels back to normal. The purpose of this study is to see if KRX-0502 (ferric citrate) is safe and effective as a phosphate binder.
Study identification
- NCT ID
- NCT01074125
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 154 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2010
- Primary completion
- Oct 31, 2010
- Completion
- Oct 31, 2010
- Last update posted
- Dec 3, 2014
2010
United States locations
- U.S. sites
- 15
- U.S. states
- 10
- U.S. cities
- 13
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Western Nephrology | Westminster | Colorado | 80031 | — |
| Pines Clinical Research, Inc. | Pembroke Pines | Florida | 33028 | — |
| Kidney Care Associates, LLC | Augusta | Georgia | 30901 | — |
| Circle Medical Management | Chicago | Illinois | 60607 | — |
| Western New England Renal & Transplant Associates | Springfield | Massachusetts | 01107 | — |
| Brookdale Physician's Dialysis Associates | Brooklyn | New York | 11212 | — |
| DCI | Cincinnati | Ohio | 45206 | — |
| Cleveland Clinical Foundation Fresenius East (Fairhill) | Cleveland | Ohio | 44104 | — |
| The Ohio State University Cramblett Medical Clinic | Columbus | Ohio | 43210 | — |
| Southeast Renal Research Institute | Chattanooga | Tennessee | 37404 | — |
| Nephrology Associates, PC | Nashville | Tennessee | 37205 | — |
| Meharry Medical College Clinical Research Center | Nashville | Tennessee | 37208 | — |
| Vanderbilt University Medical Center Clinical Trials Center | Nashville | Tennessee | 37232-1371 | — |
| Kidney Associates | Houston | Texas | 77030 | — |
| Centre Point Dialysis | West Allis | Wisconsin | 53214 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 1 non-U.S. site.
Recently updated Hyperphosphatemia trials
Other public records listing Hyperphosphatemia. Sorted by last update posted; newest first. Not a recommendation.
- NCT06712654: A Study to Evaluate Safety, Tolerability and Efficacy of AP306 at Fixed Doses in Dialysis Participants With Hyperphosphatemia Recruiting
- NCT04278404: Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) Recruiting
- NCT06933472: A Study of a Novel Iron-based Phosphate Binder AP301 in Patients With Hyperphosphatemia in the U.S. and China Recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01074125, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 3, 2014 · Synced Sep 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01074125 live on ClinicalTrials.gov.